SITE013-0223

SITE013 (USA) › SITE013-0223

SITE013-0223

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2026-05-24

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-11 (study day 11); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.